Inovio Pharmaceuticals Inc vs SPDR Kensho Final Frontiers ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while SPDR Kensho Final Frontiers ETF trades at $103.49 (market cap $170.14M). The key difference: SPDR Kensho Final Frontiers ETF is the larger of the two by market cap, and SPDR Kensho Final Frontiers ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and SPDR Kensho Final Frontiers ETF for 9 Days on average.
| INO | ROKT | |
|---|---|---|
Market Cap | $112.19M | $170.14M |
Volume | 3,201,278 | 12,298 |
Sector | Health | Sector/Thematic |
52-Week High | $2.65 | $136.68 |
52-Week Low | $0.66 | $72.93 |
Typical Hold Time | 43 Days | 9 Days |
Enterprise Value | $83.51M | — |
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →